Illumina in research collaboration with AstraZeneca on drug target discovery
metamorworks/iStock via Getty Images         


Illumina (NASDAQ:ILMN) has entered into a collaboration agreement with AstraZeneca (NASDAQ:AZN) to utilize their respective expertise in artificial intelligence, genomic interpretation, and genomic analysis to accelerate drug target discovery.
The collaboration is designed to determine whether using these technologies can boost target discovery to find new drugs based on human omics insights.
Illumina's (ILMN) next generation of AI-based interpretation tools, PrimateAI and SpliceAI. They will be used by AstraZeneca's (AZN)Â Centre for Genomics Research to analyze large-scale multi-omics data sets.
Read why Seeking Alpha contributor Bashar Issa believes that Illumina (ILMN) is overvalued.